Benzinga
Benzinga
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Benzinga
mardi, novembre 17
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Contineum Therapeutics Inc
CTNM
NASDAQ
Liste de surveillance
Get Report
Trade with Public
Get Report
Trade with Public
$9.67
Dern. MÀJ: Nov 16, 4:00 PM
Get Report
Aperçu
Actualités
Graphiques
Prévisions de résultats
Événements
Objectifs de cours
Données financières
Sentiment
Actionnariat
Comparer
Options
Rapport sur les stocks
Contineum Therapeutics Financials
Contineum Therapeutics (CTNM) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Contineum Therapeutics Q3 EPS $(0.49) Misses $(0.45) Estimate
Contineum Therapeutics (NASDAQ:CTNM) reported quarterly losses of $(0.49) per share which missed the analyst consensus estimate of $(0.45) by 8.89 percent. This is a 8.89 percent decrease over losses of $(0.45) per
Benzinga Newsdesk
PRO
Contineum Therapeutics Q2 EPS $(0.40) Beats $(0.48) Estimate
Contineum Therapeutics (NASDAQ:CTNM) reported quarterly losses of $(0.40) per share which beat the analyst consensus estimate of $(0.48) by 16.67 percent. This is a 35.48 percent increase over losses of $(0.62) per
Benzinga Newsdesk
PRO
Contineum Therapeutics Q1 EPS $(0.39) Beats $(0.51) Estimate
Contineum Therapeutics (NASDAQ:CTNM) reported quarterly losses of $(0.39) per share which beat the analyst consensus estimate of $(0.51) by 23.53 percent. This is a 37.1 percent increase over losses of $(0.62) per share
Benzinga Newsdesk
Contineum Therapeutics Q4 Earnings Summary & Key Takeaways
Benzinga Insights
PRO
Contineum Therapeutics Q4 EPS $(0.49) Beats $(0.59) Estimate
Contineum Therapeutics (NASDAQ:CTNM) reported quarterly losses of $(0.49) per share which beat the analyst consensus estimate of $(0.59) by 16.67 percent. This is a 12.5 percent increase over losses of $(0.56) per share
Benzinga Newsdesk
PRO
Contineum Therapeutics Q3 EPS $(0.45) Beats $(0.60) Estimate
Contineum Therapeutics (NASDAQ:CTNM) reported quarterly losses of $(0.45) per share which beat the analyst consensus estimate of $(0.60) by 24.75 percent. This is a 12.5 percent decrease over losses of $(0.40) per share
Benzinga Newsdesk